Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2010 Jan;76(1):14–22. doi: 10.1016/j.ijrobp.2009.01.062

Table 1. Pretreatment Characteristics.

Dose Level I (68.4Gy
@ 1.8Gy/Fraction)
Dose Level II (73.8Gy
@ 1.8Gy/Fraction)
Dose Level III (79.2Gy
@ 1.8Gy/Fraction)
Dose Level IV (74Gy
@ 2.0Gy/Fraction)
Dose Level V (78Gy
@ 2.0Gy/Fraction)

Group 1
(n=75)
Group 2
(n=33)
Group 3
(n=4)
Group 1
(n=97)
Group 2
(n=108)
Group 3
(n=95)
Group 1
(n=104)
Group 2
(n=63)
Group 1
(n=115)
Group 2
(n=141)
Group 1
(n=119)
Group 2
(n=101)

Age < 70 53% 39% 100% 43% 48% 54% 67% 56% 51% 43% 54% 48%
≥ 70 47% 61% 0% 57% 52% 46% 33% 44% 49% 57% 46% 52%

T-Stage T1 56% 27% 0% 67% 29% 0% 54% 27% 65% 40% 68% 46%
T2 44% 73% 0% 33% 71% 0% 46% 73% 35% 60% 32% 54%
T3 0% 0% 100% 0% 0% 100% 0% 0% 0% 0% 0% 0%

Institutional Gleason 2-6 93% 36% 50% 95% 41% 28% 94% 22% 91% 21% 87% 12%
7 7% 36% 25% 5% 41% 44% 6% 46% 9% 56% 13% 71%
8-10 0% 27% 25% 0% 19% 27% 0% 32% 0% 23% 0% 17%

Initial PSA ≤ 10 75% 42% 0% 81% 43% 35% 87% 43% 86% 50% 77% 43%
11-20 24% 33% 25% 19% 35% 37% 13% 38% 14% 32% 23% 41%
≥ 20 1% 24% 75% 0% 22% 28% 1% 19% 0% 18% 0% 17%

Induction Hormones Yes 8% 15% 50% 20% 48% 87% 30% 68% 22% 52% 8% 34%

Mean ICRU reference dose Gy ± (sd) 71.1 ± 1.5 71.3 ± 1.3 71.2 ± 1.3 76.7 ± 1.6 77.3 ± 1.5 77.4 ± 1.2 81.2 ± 1.6 82.3 ± 1.4 77.1 ± 1.3 77.0 ± 1.2 81.6 ± 1.1 81.2 ± 1.2

Median Follow-up All Patients Years
(range)
9.4
(1.5,12.4)
9.6
(0.1,12.3)
10.3
(6.4,12.1)
9.9
(1.3,11.7)
8.5
(0.9,12.0)
7.4
(0.2,11.6)
8.5
(1.1,10.5)
9.2
(3.5,10.6)
7.7
(1.0,8.7)
7.0
(0.9,8.5)
5.9
(0.1,7.3)
6.1
(0.5,7.1)

Median Follow-up Surviving Patients Years
(range)
10.0
(3.0,12.4)
11.1
(3.7,12.3)
12.1
(12.1,12.1)
10.2
(3.1,11.7)
10.1
(0.9,12.0)
7.8
(0.3,11.6)
8.9
(2.1,10.5)
9.3
(4.9,10.6)
7.8
(1.0,8.7)
7.2
(2.8,8.5)
6.1
(1.3,7.3)
6.2
(2.1,7.1)